绥美凯的注意事项有什么呢？

In 2018, GlaxoSmithKline (GSK) announced that its joint venture ViiV Healthcare's single-pill compound preparation for the treatment of HIV, which is based on the new generation integrase inhibitor Tevicai (dolutegravir), was officially launched in mainland China. This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China. Existing research shows that one year (48 weeks) after HIV infection treatment, 93% of HIV-infected patients turned negative. Today let’s take a look at what are the precautions for Suimeikai?

1. Medication for elderly patients: In patients aged 65 and above, there are limited data on the use of dolutegravir, abacavir and lamivudine. There is no evidence that older patients require different dosages than younger adult patients. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when administering the drug in this age group. 

2. It is prohibited to be used in patients with known hypersensitivity to dolutegravir, abacavir, lamivudine or any excipients.

  3. It is prohibited to use it in combination with dofetilide and pixicanide. 

4. Osteonecrosis: Cases of osteonecrosis have been reported, especially in patients with recognized risk factors, advanced HIV disease, or long-term exposure to combination antiretroviral therapy (CART). It's unclear how often it occurs. 

5. Immune reconstitution inflammatory syndrome: In severely immunodeficient patients infected with HIV, when starting combination antiretroviral therapy (CART), an inflammatory response may occur to asymptomatic or residual opportunistic pathogenic infections. Autoimmune disorders (e.g., Graves' disease) have also been reported; however, the reported timing of onset is inconsistent and these events may occur many months after initiation of treatment. 

6. Chronic hepatitis B or hepatitis C co-infection: In the phase III study of dolutegravir, patients co-infected with hepatitis B and/or hepatitis C virus are allowed to be recruited, provided that during the baseline period, the liver function test value does not exceed 5 times the upper limit of normal (ULN). Overall, the safety profile in patients with hepatitis B and/or hepatitis C virus infection was similar to that in patients without hepatitis B or C virus infection, but the incidence of AST and ALT abnormalities was higher in the hepatitis B and/or hepatitis C infection subgroup across all treatment groups. 

7. Medication for children: The safety and effectiveness of Suimeikai (dolute abalamib tablets) for children under 12 years of age has not yet been determined. No data yet.

The above is the content of the precautions, I hope it can help you!